Download PDF

Introduction

Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeth's Prevnar or Merck & Co's Gardasil, along with the emergence of novel vaccine technologies and favourable legislation have brought vaccines back into the main focus of pharmaceutical and biotech companies.

Scope

• Market overview with current market assessment in terms of leading players, brands and geographies
• In-depth analyses of the leading 5 players' portfolios, R&D pipelines, sales trends, geographic spread, licensing patterns and strategic outlook
• Discussion of key developments shaping the sector: new technologies, indications and geographies
• Snapshot profiles of second tier companies in the sector: strength in specialties

Highlights

With the exception of influenza, only two to three vaccine manufacturers compete for each disease. This lack of competition combined with public health requirements to guarantee a stable supply of vaccines has resulted in a recent upward shift of vaccine prices for specialty vaccines.

The most significant threat to the oligopoly of the Big 5 in the vaccines market comes from companies from emerging markets, which have large manufacturing capacities for biologics and are able to produce even complex substances like vaccines at low costs.

While vaccine sales have grown at a CAGR of 32% between 2004 and 2007 and shown an annual growth rate of 46% between 2006 and 2007, overall pharmaceutical sales have grown much more slowly, with both the 2004-2007 CAGR as well as the growth rate between 2006 and 2007 only reaching 8%.

Reasons to Purchase

• Get a comprehensive, insightful commercial overview of the vaccines market
• Learn about the strategies of the Big 5 players, their strengths, weaknesses, similarities and differences
• Gain insight into the future directions and growing strategic importance of vaccines for Big Pharma

View Table Of Contents >